| Literature DB >> 30551175 |
Henrik Devitt Møller1, Lin Lin2, Xi Xiang2,3,4, Trine Skov Petersen2, Jinrong Huang1,4,5,6, Luhan Yang7, Eigil Kjeldsen8, Uffe Birk Jensen2,8, Xiuqing Zhang3,5,6, Xin Liu4,5,6, Xun Xu4,5,6, Jian Wang4,5,6,9, Huanming Yang4,5,6,9, George M Church7,10, Lars Bolund2,4,5,11, Birgitte Regenberg1, Yonglun Luo2,4,5,6,11.
Abstract
Extrachromosomal circular DNA (eccDNA) and ring chromosomes are genetic alterations found in humans with genetic disorders. However, there is a lack of genetic engineering tools to recapitulate and study the biogenesis of eccDNAs. Here, we created a dual-fluorescence biosensor cassette, which upon the delivery of pairs of CRISPR/Cas9 guide RNAs, CRISPR-C, allows us to study the biogenesis of a specific fluorophore expressing eccDNA in human cells. We show that CRISPR-C can generate functional eccDNA, using the novel eccDNA biosensor system. We further reveal that CRISPR-C also can generate eccDNAs from intergenic and genic loci in human embryonic kidney 293T cells and human mammary fibroblasts. EccDNAs mainly forms by end-joining mediated DNA-repair and we show that CRISPR-C is able to generate endogenous eccDNAs in sizes from a few hundred base pairs and ranging up to 207 kb. Even a 47.4 megabase-sized ring chromosome 18 can be created by CRISPR-C. Our study creates a new territory for CRISPR gene editing and highlights CRISPR-C as a useful tool for studying the cellular impact, persistence and function of eccDNAs.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30551175 PMCID: PMC6294522 DOI: 10.1093/nar/gky767
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1.A dual-fluorescence eccDNA biosensor system and CRISPR-C for studying eccDNA biogenesis in human cells. (A) Model of TRE-ECC biosensor after two double-stranded breaks by CRISPR-C (Cr1 and Cr2), leading to [EGFP] and ΔEGFP or EGFP inversion. (B) Scheme of TRE-ECC biosensor. (C) Experimental outline. (D) TRE-ECC plasmid assessment by fluorescence microscopy after Cr1+Cr2 using pUC19 as control (uncut). (E, upper part) Outline of stable genomic integration of TRE-ECC in HEK293T. (F) Copy-number assessment by Southern blot with EGFP-probe after KpnI digestion. (E, lower part) Outline for Cr1+Cr2 activation of integrated TRE-ECC. (G) Representative result from FACS analysis of clone 1 in the absence or presence of tetracycline (Tet). (H) Histograms of fluorescence cell percentages of all 15 isolated TRE-ECC clones after Cr1+Cr2 and FACS analysis. (I) PCR and Sanger sequencing validation of genotypes on exonuclease-treated DNA, displayed in A, after Cr1+Cr2 for TRE-ECC clone 1 and clone 4. C, negative CRISPR control; NC, non-template control. (J) Southern blot, probed with EGFP on HEK293T purified and digested DNA from untreated (C, KpnI) and Cr1+Cr2 treated cells. X = XbaI, H = HindIII.
Figure 2.Endogenous DNA circularization by CRISPR-C. (A) Chromosome 1 map 2 kb downstream of the CRP locus. gRNA: Cr3, Cr4; diagnostic oligos: p5 to p8. (B) Experimental outline. (C–E) Gel-images of corresponding PCR products across junctions after testing for (C) DNA deletion, 0.64 kb; wildtype, 1.23 kb), (D) inversion and (E) circular DNA, next to resultant chromatograms from Sanger sequencing. (F) Chromosome 10 map at the PLAU (UPA) locus. gRNA, Cr5 and Cr6, diagnostic oligos; p9 to p12. (G) PCR and sequencing confirmation of the [UPA]. (H) Chromosome 19 map at the TRIM28 locus. (I) PCR and sequencing confirmation of the [TRIM28]. (J–K) Indel distribution across the junction of [dsCRP] generated in HEK293T and HMF cells, respectively. For (E), (G) and (I), exonuclease-treated DNA was used as template.
Figure 3.Stability of eccDNAs generated by CRISPR-C. (A) Outline of time-course experiment. (B) Left, percent fluorescence cells from 1 to 6 cell passages (1:3 split-ratio) in absence of tetracycline (-Tet); right, corresponding FACS gating images. (C) As B description, cells propagated in +Tet conditions. (D) Outward PCR analysis of [EGFP] at passage 1 to 6; left, -Tet; right, +Tet. Cr1+Cr2 (1+2), CRISPR gRNAs; C, control – gRNA; ctrl, DNA template control. (E) Quantification of PCR analysis by Image J, solid lines; theoretical 1/3 dilution rate, dash lines.
Figure 4.Generation of eccDNAs of various sizes and ring chromosome 18 by CRISPR-C. (A, upper part) Schematic view of distances between targeted CRISPR gRNAs on chromosome 1 (Cr9 to Cr17) along with diagnostic oligos (p17 to p26) for PCR confirmation of formation of (A, lower part) kb-sized [CRP] and corresponding CRP deletions, ΔCRP. (B and C) Chromatograms of Sanger sequencing across the junction of the [CRP] and the [CRP] in both directions and chromatograms below confirming CRP deletions, ΔCRPand ΔCRP. (D) Left, schematic view of chromosome 18 with annotated Cr18 to Cr21 sites and resultant formation of Ring and Δchr18 after CRISPR-C and DNA repair. Right, Sanger sequencing chromatograms confirming expected junctions. (E) Corresponding gel-images of amplified PCR products across junctions associated to D. Schemes, not drawn to scale. (F) Karyotyping ring18-like structure of chromosome 18 by telomere staining (Telo) and whole chromosome 18 painting (WCP18) of HEK293T cells treated with CRISPR-C. Blue, DAPI staining of DNA; Red, telomere; Cyan, chromosome 18.